Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: J Drug Target. 2018 Jan 10;26(5-6):435–447. doi: 10.1080/1061186X.2017.1419363

Table 4.

A comparison of drug-combination nanoparticle products CPX-351 and TLC-ART 101 with respect to physical and pharmacokinetic characteristics and manufacturing process.

CPX-351a TLC-ART 101b
Disease indication Acute myeloid leukaemia HIV/AIDS
Physical properties
Characteristics liposomes Drug combination particles (excipient stabilised drug particles)
Hydrodynamic size 100 ± 20 nm ~52 nm
Excipients DSPC, DSPG, cholesterol DSPC, DSPE-mPEG2000
Drugs and solubility Daunorubicin (LogP = 1.83); Cytarabine (LogP = −2.8) Lopinavir (LogP = 5.94); Ritonavir (LogP = 4.24); Tenofovir (LogP = −1.6)
Drug ratios (molar)c 1:5 4:1:5
Manufacturing process
Manufacturing stepsd graphic file with name nihms956172t1.jpg graphic file with name nihms956172t2.jpg
Pharmacokinetic characteristics
t1/2 31.5 h (Daunorubicin), 40.4 h (Cytarabine) 476.9 h (Lopinavir), 44.1 h (Ritonavir), 65.3 h (Tenofovir)
a

CPX-351 is a liposomal formulation consisting daunorubicin and cytarabine with fixed ratio for treatment of AML.

b

TLC-ART 101 is a lipid nanoparticle formulation consisting lopinavir, ritonavir and tenofovir with fixed ratio for treatment of HIV/AIDS.

c

Drug ratios in these formulations molar ratios of daunorubicin:cytarabine and lopinavir:ritonavir:tenoforvir, respectively.

d

The steps indicate simplified key procedures in manufacturing of CPX-351 and TLC-ART 101.